Odds F C, Oris M, Van Dorsselaer P, Van Gerven F
Department of Molecular and Cell Biology, University of Aberdeen, Institute of Medical Sciences, Aberdeen AB25 2ZD, Scotland, United Kingdom.
Antimicrob Agents Chemother. 2000 Nov;44(11):3180-3. doi: 10.1128/AAC.44.11.3180-3183.2000.
An intravenous (i.v.) formulation of itraconazole was evaluated in disseminated fungal infection models in guinea pigs. In acute disseminated Candida albicans and Aspergillus fumigatus infections, treatment at 5 mg/kg of body weight twice a day (b.i.d.) significantly prolonged survival. In these models and in animals with chronic disseminated cryptococcosis, itraconazole given i.v. at 2.5 and 5 mg/kg b.i.d. greatly reduced the proportions of organs with culture-detectable fungal burdens. The efficacy of i.v. itraconazole in these animal models justifies its further investigation for the treatment of life-threatening mycoses in humans.
对伊曲康唑的静脉注射制剂在豚鼠播散性真菌感染模型中进行了评估。在急性播散性白色念珠菌和烟曲霉感染中，以5mg/kg体重每日两次（bid）进行治疗可显著延长生存期。在这些模型以及患有慢性播散性隐球菌病的动物中，静脉注射2.5mg/kg和5mg/kg bid的伊曲康唑可大幅降低可通过培养检测到真菌负荷的器官比例。静脉注射伊曲康唑在这些动物模型中的疗效证明有必要对其进一步研究，以用于治疗人类危及生命的真菌病。
